Immune checkpoint inhibitors (ICIs) are increasingly being used to manage multiple tumor types. Unfortunately. immune-related adverse events affect up to 60% of recipients. often leading to treatment discontinuation in settings where few alternative cancer therapies may be available. https://www.allpeoplesay.com/product-category/wholesale/